Breast Cancer Research and Treatment

, Volume 2, Issue 1, pp 75–84 | Cite as

Adjuvant therapy of breast cancer 1971–1981

Ten years of progress
  • Paul P. Carbone
Fourth Annual San Antonio Breast Cancer Symposium


Adjuvant therapy in the past 10 years has gone from experimental to clinical practice for women who are premenopausal. For the postmenopausal and the elderly patient the treatment for some is still experimental and for others proven. Obviously, we need to collect data for all patients because we do not have information on 10 or 20 year survivals, the long-term effects of chemotherapy, or the role of adjuvant hormonal therapy. Likewise further trials are needed to define the optimal duration of treatment, the role of adriamycin combinations, and the utility of chemotherapy in node negative patients. Future trials will undoubtedly include lesser surgery options. The hope of the future lies in the definition of more specific options for treatment, avoiding the unnecessary toxicity of radical surgery, extensive X-ray therapy or needless chemotherapy. These answers will come from well-designed clinical trials, well-integrated with good laboratory studies designed to explore biological as well as mechanistic questions.


adjuvant therapy breast cancer clinical trials 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    DeVita VT: Recent perspectives on drug resistance.In S Salmon and S Jones (eds): Adjuvant Therapy III. Grune and Stratton, New York, 1981, pp 3–11.Google Scholar
  2. 2.
    Fisher B: A commentary on the role of the surgeon in primary breast cancer. Breast Cancer Res Treat 1: 17–26, 1981.PubMedGoogle Scholar
  3. 3.
    Carbone PP: Chemotherapy in the treatment strategy of breast cancer. Cancer 36: 633–637, 1975.PubMedGoogle Scholar
  4. 4.
    Fisher B, Slack NH, Bross IDJ: Ten year follow-up results of patients with carcinoma of the breast in a cooperative clinical trial evaluating surgical adjuvant chemotherapy. Surg Gyn Obstet 140: 528–534, 1975.Google Scholar
  5. 5.
    Fisher B, Slack NH, Cavanaugh PJ, Gardner B, Ravdin RG, and cooperating investigators: Postoperative radiotherapy in the treatment of breast cancer: Results of the NSABP clinical trial. Ann Surg 172: 711–732, 1970.PubMedGoogle Scholar
  6. 6.
    Atkins H, Hayward JL, Klugman DJ, Wazte AB: Treatment of early breast cancer: A report after 10 years of a clinical trial. Brit Med J 2: 423–429, 1972.PubMedGoogle Scholar
  7. 7.
    Peters V: Wedge resection and irradiation, an effective treatment in early breast cancer. JAMA 200: 134–135, 1967.PubMedGoogle Scholar
  8. 8.
    McWhirter R: Simple mastectomy and radiotherapy in the treatment of breast cancer. Brit J Radiology 28: 128–139, 1955.Google Scholar
  9. 9.
    Gilchrist K: personal communication.Google Scholar
  10. 10.
    Fisher B, Ravdin RG, Ausman RK, Slack NH, Moore GE, Noer RJ: Surgical adjuvant chemotherapy in cancer of the breast: Results of a decade of cooperative investigation. Ann Surg 168: 337–356, 1968.PubMedGoogle Scholar
  11. 11.
    Nissen-Meyer R: One short-term chemotherapy in primary breast cancer: 12 year follow-up in series 1 of the Scandinavian Adjuvant Chemotherapy Study Group.In S Jones and S Salmon (eds): Adjuvant Therapy II. Grune and Stratton, New York, 1979, pp 207–214.Google Scholar
  12. 12.
    Carbone PP, Baier M, Band P et al.: Chemotherapy of disseminated breast cancer: Current status and prospects. Cancer 39: 2916–2922, 1977.PubMedGoogle Scholar
  13. 13.
    Martin DS: An appraisal of chemotherapy as an adjuvant to surgery for cancer. Am J Surg 97: 685, 1959.PubMedGoogle Scholar
  14. 14.
    Schabel FM: Surgical adjuvant chemotherapy of metastatic murine tumors. Cancer 40: 558–568, 1977.PubMedGoogle Scholar
  15. 15.
    Fisher B: Laboratory and clinical research in breast cancer — a personal adventure. Cancer Res 40: 3863–3874, 1980.PubMedGoogle Scholar
  16. 16.
    Cannellos GP, DeVita VT, Gold GL, Chabner BA, Schein PS, Young RC: Cyclical combination chemotherapy for advanced breast cancer. Brit Med J 1: 218–220, 1974.PubMedGoogle Scholar
  17. 17.
    Cannellos GP, Pocock SJ, Taylor SG, Sears ME: Combination chemotherapy for metastatic breast cancer: Prospective comparison of multiple drug therapy with 1-phenylalanine mustard. Cancer 38: 1182–1888, 1976.Google Scholar
  18. 18.
    Sears ME, Haut A, Eckles N: Melphalan (NSC8806) in advanced breast cancer. Cancer Chemother Rep 50: 271–279, 1971.Google Scholar
  19. 19.
    Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, Redmond C, Zelen M, Band P, Katrych DL, Wolmark N, Fisher ER: 1-Phenylalanine mustard, L-PAM in the management of early breast cancer: A report of early findings. N Engl J Med 292: 117–122, 1975.PubMedGoogle Scholar
  20. 20.
    Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, Delena M, Tancini G, Bajetta E, Musumeci R, Veronesi U: Combination chemotherapy as adjunct treatment in operable breast cancer. N Engl J Med 294: 405–410, 1976.PubMedGoogle Scholar
  21. 21.
    Rossi A, Bonadonna G, Valagussa P, Veronesi U: Multimodal treatment in operable breast cancer: Five year results of the CMF program. Brit Med J 282: 1427–1431, 1981.Google Scholar
  22. 22.
    Ahman DL, Payne WS, Scanlon PW, O'Fallon JR, Bisel HF, Hahn RG, Edmonson JH, Ingle JN, Frytak S, O'Connell MJ, Rubin J: Repeated adjuvant therapy with phenylalanine mustard or 5 fluorouracil, cyclophosphamide and prednisone with or without radiation after mastectomy. Lancet 2: 893–896, 1978.Google Scholar
  23. 23.
    Caprini JA, Oviedo MA, Cunningham MP, Cohen E, Trueheart RE, Khandekar JD, Scanlon E: Adjuvant chemotherapy for stage II and III breast cancer. JAMA 244: 243–246, 1980.PubMedGoogle Scholar
  24. 24.
    Hubay CA, Pearson OH, Marshall JS, Stellato TA, Rhodes RS, DeBonne SM, Rosenblatt J, Mansour EG, Herman RE, Jones JC, Flynn WJ, Eckert C, McGuire WL: Adjuvant therapy in stage II breast cancer. Breast Cancer Res Treat 1: 77–82, 1981.PubMedGoogle Scholar
  25. 25.
    Tormey DC, Holland JF, Weinberg V, Weiss R, Falkson G, Glidewell O, Leone L, Perloff M: 5 drug versus 3 drug ± MER postoperative chemotherapy for mammary carcinoma.In S Salmon and S Jones (eds): Adjuvant Therapy III. Grune and Stratton, New York, 1981, pp 377–384.Google Scholar
  26. 26.
    Rivkin S, Glucksberg H, Rasmussen S: Adjuvant chemotherapy for operable breast cancer with positive nodes (abstract). Breast Cancer Res Treat 1: 176, 1981.Google Scholar
  27. 27.
    Meakin JW, Allt WEC, Beale FA, Brown TC, Bush RS, Clark RM, Fitzpatrick PJ, Hawkins NV, Jenkin RDT, Pringle JF, Reid JG, Rider JL, Hayward JL, Bulbrook RD: Ovarian irradiation and prednisone following surgery and radiotherapy for carcinoma of the breast. Canad Med Assoc J 120: 1221–1229, 1979.PubMedGoogle Scholar
  28. 28.
    Fisher B, Redmond C, Brown A, Wolmark N, Wittliff J, Fisher ER, Plotken D, Bowan D, and other NSAB investigators: Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 305: 1–6, 1981.PubMedGoogle Scholar
  29. 29.
    Band PR, Tormey DC, Temkin N: Induction chemotherapy and maintenance chemohormone therapy in metastatic breast cancer (abstract). Am Assoc Cancer Res 7: 37, 1976.Google Scholar
  30. 30.
    Bonadonna G, Valagussa P, Rossi A, Tancini G, Brambilla C, Marchini S, Veronesi U: Multimodal therapy with CMF in resectable breast cancer with positive axillary nodes: The Milan Institute experience.In S Salmon and S Jones (eds): Adjuvant Therapy III. Grune and Stratton, New York, 1981, pp 435–444.Google Scholar
  31. 31.
    Vélez-García E, Moore M, Marcial V, Lefante J, Ketcham A, Smalley R: Adjuvant short and long term chemotherapy ± radiotherapy in stage II breast cancer — the Southeastern Cancer Study Group experience (abstract). Breast Cancer Res Treat 1: 176, 1981.Google Scholar
  32. 32.
    Cooper R, Muss H, Ferree C, Richards F, Stuart J, White D, Wells B, Pope E, Spurr C: Follow-up evaluation of a randomized adjuvant study of chemotherapy with and without irradiation therapy for stage II breast cancer (abstract). Breast Cancer Res Treat 1: 176, 1981.Google Scholar
  33. 33.
    Glick JH, Creech RH, Torri S, Holroyde C, Brodovsky H, Catalano RB, Varano M: Randomized clinical trial of tamoxifen plus sequential CMF chemotherapy versus tamoxifen alone in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 1: 59–68, 1981.PubMedGoogle Scholar
  34. 34.
    Jordan VC, Dix CF, Allen KE: The effectiveness of long term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer.In SE Jones and SE Salmon (eds): Adjuvant Therapy of Cancer II. Grune and Stratton, New York, 1979, pp 19–26.Google Scholar
  35. 35.
    Hammond N, Jones SE, Salmon SE, Patton D, Woolfenden J: Predictive value of bone scans in an adjuvant breast cancer program. Cancer 41: 138–142, 1978.PubMedGoogle Scholar
  36. 36.
    Skipper HE: Kinetics of mammary tumor cell growth and implication for therapy. Cancer 28: 1479–1499, 1971.Google Scholar
  37. 37.
    Hart RD, Perloff M, Holland JF: One day VATH (vinblastine, adriamycin, thiotepa and halotestin) therapy for advanced breast cancer refractory to chemotherapy. Cancer 48: 1522–1527, 1981.PubMedGoogle Scholar
  38. 38.
    Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 63: 1727–1731, 1979.PubMedGoogle Scholar
  39. 39.
    Begg CB, Carbone PP: Personal communication, 1981.Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1982

Authors and Affiliations

  • Paul P. Carbone
    • 1
  1. 1.Wisconsin Clinical Cancer Center and Eastern Cooperative Oncology GroupMadisonUSA

Personalised recommendations